Analysts Set Celcuity, Inc. (NASDAQ:CELC) Price Target at $155.18

Shares of Celcuity, Inc. (NASDAQ:CELC) have been assigned an average rating of “Moderate Buy” from the twelve ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and eleven have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $155.1818.

Several equities research analysts recently issued reports on CELC shares. Wells Fargo & Company dropped their price target on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 3rd. Leerink Partners set a $155.00 price objective on shares of Celcuity in a research report on Tuesday, June 2nd. Citizens Jmp raised their target price on Celcuity from $160.00 to $177.00 and gave the company a “market outperform” rating in a research note on Wednesday, July 15th. HC Wainwright lifted their target price on Celcuity from $145.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Finally, Citigroup reiterated an “outperform” rating on shares of Celcuity in a research note on Wednesday, July 15th.

Insider Buying and Selling

In other Celcuity news, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the sale, the director directly owned 6,760 shares in the company, valued at $949,509.60. The trade was a 57.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the sale, the director owned 65,000 shares in the company, valued at $9,144,200. This represents a 27.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by company insiders.

Institutional Trading of Celcuity

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. PNC Financial Services Group Inc. lifted its position in shares of Celcuity by 20.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock worth $59,000 after buying an additional 86 shares during the last quarter. Ogorek Anthony Joseph NY ADV grew its position in shares of Celcuity by 19.7% during the 4th quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock valued at $66,000 after buying an additional 109 shares during the last quarter. US Bancorp DE grew its position in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares during the last quarter. Intech Investment Management LLC raised its stake in Celcuity by 1.4% during the fourth quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock worth $1,295,000 after acquiring an additional 183 shares during the period. Finally, Aristides Capital LLC raised its stake in Celcuity by 2.0% during the fourth quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock worth $1,526,000 after acquiring an additional 303 shares during the period. Institutional investors own 63.33% of the company’s stock.

Celcuity Stock Up 4.2%

Shares of NASDAQ:CELC opened at $91.69 on Friday. The company has a market capitalization of $4.47 billion, a price-to-earnings ratio of -23.51 and a beta of 0.16. The company has a 50 day moving average of $106.76 and a two-hundred day moving average of $110.72. Celcuity has a 52-week low of $13.50 and a 52-week high of $151.02. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last posted its earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. As a group, analysts forecast that Celcuity will post -3.76 earnings per share for the current fiscal year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.